CliffBio
small molecule

LATUDA

LURASIDONE HYDROCHLORIDE

Loss of exclusivityNovember 2031latest FDA-listed patent expiry
CompanySunovion →View the full company profile on CliffBio

Drug detail

Brand nameLATUDA
Active ingredientLURASIDONE HYDROCHLORIDE
Strength40MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2010
Marketing statusRX

Listed patents

PatentExpiresType
9259423*PEDNovember 2031—
9259423May 2031use U-1822
9827242May 2031use U-2201
8883794*PEDNovember 2026—
8729085*PEDNovember 2026—
9907794*PEDNovember 2026—
9907794May 2026product
9555027May 2026product
8883794May 2026product
8729085May 2026product

More from Sunovion

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

LATUDA patent cliff — loss of exclusivity November 2031 | CliffBio